In 2017, Kohling Kravis Roberts and Aisling Capital launched Ajax Health to identify, invest in and scale new technologies in the medical device space. They appointed Duke Rohlen as CEO for Ajax Health.
Announced in January of 2017, Ajax Health raised $95 million in funding. The round was led by Kohlberg Kravis Roberts and included participation from Duke Rohlen and Aisling Capital.
Ajax Health announced the close of their Series B funding in July of 2018 at $120 million. The round was oversubscribed, and included investment from ICONIQ Capital, HealthQuest Capital, Polaris Partners, WTI, Kohlberg Kravis Roberts and Aisling Capital.
Announced in April 2019, Ajax Health raised $85 million. HealthQuest Capital led the round which included participation from Aisling Capital and Polaris Partners.
In June of 2019, Ajax announced a further $15 million raised to complete the round and their Ajax II fund at $100 million. Ajax used a portion of the funding to back Cortica Inc. and Ablacon. Ablacon is developing AI-powered atrial fibrillation mapping.
Ajax Health raised $100 million for their Ajax II fund in June 2019. Through Ajax II, they sought investment in companies with new medtech devices and potential for high-exit demand where returns could be realized in 48 months. They invested in Cortica Inc. and Ablacon through AJax II.
Announced in September 2019, Ajax Health raised $100 million for their fund. HealthQuest Capital led the round which included participation from Polaris Partners. Through Ajax III, Ajax Health seeks to invest in companies in the fields of medical technologies, healthcare services and health IT.
Advanced Cardiac Therapeutics (ACT) announced the close of a funding round in May of 2017. AJax Health led the round which concluded at $45 million. ACT developed a catheter ablation system to treat atrial fibrillation.
Announced April 2019, Ajax Health led Ablacon's Series A financing. The round raised a total of $21.5 million. Ablacon's Electrographic Flow uses AI and machine learning to analyze and visualize the flow of action potentials and detect signs of atrial fibrillation.
Ajax Health led EP Map-System's Series A financing. The total round was for $25 million. EP Map-System developed a suite of technologies focused on electrophysiology.